Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L, Saito M, Thar Min AK, Saito K, Ashizawa M, Kase K, Nakajima S, Onozawa H, Okayama H, Endo H, Fujita S, Sakamoto W, Saze Z, Momma T, Mimura K, Ohki S, Kono K.
Yamada L, et al. Among authors: nakajima s.
Gastric Cancer. 2021 Jan;24(1):60-71. doi: 10.1007/s10120-020-01094-0. Epub 2020 Jun 6.
Gastric Cancer. 2021.
PMID: 32506298